IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

WESTBROOK, Maine--(BUSINESS WIRE)--Aug 11, 2026--

IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst™ proBNP Test, the first and only dual-species, in-clinic test for NT-proBNP, expanding cardiac capabilities across its connected point-of-care and reference laboratory portfolio. The test measures a well-established biomarker used to evaluate heart disease in companion animals, a condition that affects approximately 1 in 6 cats 1 and 1 in 10 dogs 2, yet remains underassessed in general practice. Available on the Catalyst platform with a global installed base of nearly 80,000 analyzers, Catalyst proBNP brings laboratory-level accuracy and real-time cardiac assessment into routine workflows, whether run on its own or alongside other chemistry tests.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811986566/en/

By delivering results during the patient visit, Catalyst proBNP provides an affordable option that reduces reliance on multistep referrals and expands what can be done at the point of care, particularly where access to echocardiography or cardiology specialists is limited. At the same time, Catalyst proBNP expands access to a global cardiac testing opportunity estimated at approximately $4 billion 3 while giving veterinarians a practical new tool to assess cardiac health.

“For many veterinarians, cardiac evaluation has often involved delays, added costs, or immediate referrals,” said Mike Erickson, President and Chief Executive Officer of IDEXX. “With Catalyst proBNP, veterinarians get clear, quantitative results in minutes, not days, so they can make informed decisions earlier. That changes how care is delivered and expands what’s possible in everyday practice.”

NT-proBNP testing supports screening, diagnosis, and disease monitoring in cats and dogs. The Catalyst proBNP Test helps identify subclinical heart disease in cats, support preoperative evaluations, and evaluate the likelihood of clinically relevant cardiac changes in healthy small- and medium-breed dogs presenting with a heart murmur. In both species, the test helps differentiate cardiac from noncardiac causes of respiratory distress and identify patients who may benefit from closer monitoring, treatment, or specialist referral.

“Cardiac disease can be difficult to detect early, particularly when clinical signs are subtle or absent,” said Sonya Gordon, BSc, DVM, DVSc, DACVIM Cardiology, Professor Cardiology, College of Veterinary Medicine and Biomedical Science, Texas A&M University.* “NT-proBNP testing provides valuable, cost-effective insight to help veterinarians identify patients with clinical or subclinical heart disease, support preanesthetic screening, and determine when additional cardiac evaluation is warranted. A quantitative NT-proBNP assay at the point of care is an important advancement, bringing objective cardiac biomarker information closer to the patient and enabling immediate integration with the physical examination, history, and other diagnostic findings.”

Catalyst proBNP results appear in VetConnect™ PLUS alongside a patient’s diagnostic history, where built-in guidance helps veterinarians interpret results in the context of the patient’s broader clinical picture. As the latest addition to IDEXX’s cardiac health offering, the test builds on a connected portfolio spanning in-clinic testing, reference laboratory services, electrocardiograms, advanced imaging, AI-assisted tools, and specialist expertise.

The Catalyst proBNP test will be available in North America beginning in October 2026, with international regions to follow. For more information, visit the Catalyst test menu web page.

*Dr. Sonya Gordon has received compensation for consulting services she has provided to IDEXX.

References

About IDEXX

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help measure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.

Note Regarding Forward-Looking Statements

This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” “project,” and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX’s filings with the United States Securities and Exchange Commission (which are available from the SEC’s EDGAR database at sec.gov and via IDEXX’s website at idexx.com).

Catalyst™ proBNP Test

BOSTON--(BUSINESS WIRE)--Aug 11, 2026--

Bruker Corporation (Nasdaq: BRKR) today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs ® technologies and AI-driven R&D with applications in pharmaceuticals, chemicals, energy, and materials. Bruker also made a minority investment in Atinary. Financial details were not disclosed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811179936/en/

Atinary intends to integrate Chemspeed configurable laboratory automation platforms, Bruker analytical instruments and SciY scientific software into its agentic AI workflows. Atinary’s code-free SDLabs ® platform applies AI agents and machine learning to design optimal experiments and deliver better and faster results with automated closed-loop Design-Make-Test-Analyze-Learn workflows. Running these integrated workflows generates high-quality, reproducible, and AI-ready datasets that are essential to train better models, increase success rates, and accelerate discovery.

Atinary and Chemspeed have established a joint demonstration laboratory at Chemspeed’s headquarters near Basel, Switzerland. Atinary’s Self-Driving Lab in Boston opened in early 2026 as a Scientific Data Factory to bring better molecules and products to market faster. The Atinary Lab includes Chemspeed robotics and Bruker benchtop NMR, as well as automation and measurement tools by other vendors, focusing on small-molecule synthesis and catalysis in pharmaceutical R&D and process development.

“Cross-coupling reactions have had a significant impact on the discovery and manufacturing of pharmaceuticals, as well as in other industries,” said Professor Stephen Buchwald, Camille Dreyfus Professor of Chemistry at MIT and Scientific Advisor to Atinary Technologies. “However, the full potential of this chemistry, particularly C-N coupling, remains untapped. Large parameter spaces, combining catalysts, ligands, bases, solvents, and temperature, are complex and difficult to navigate. Generating rigorous, reproducible, lab-validated datasets could lead to significant advances. I am excited to be a part of the Atinary team and to explore what is possible when their approaches are employed to tackle meaningful scientific challenges in their lab.”

"Atinary's mission is to augment humans with AI and robotics to accelerate scientific discovery exponentially and tackle key planetary challenges," said Dr. Hermann Tribukait, Co-Founder and CEO of Atinary Technologies. "Together with our team, ecosystem, and clients, we design and enable Self-Driving Labs as R&D flywheels, where every experiment makes the next one smarter, compounding the information from real-world lab data."

“Our strategic investment in Atinary advances Bruker’s goal to combine differentiated analytical technologies with lab automation, scientific software and AI-guided experimentation,” said Bernd Gleixner, President of the Chemspeed Division. “The Atinary SDLabs in Basel and Boston demonstrate closed-loop R&D workflows powered by agentic AI. We intend to build on this foundation by extending the collaboration to additional analytical solutions and customer applications.”

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy, as well as in industrial and cleantech research, and semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, proteomics and multiomics, spatial and single-cell biology, structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

About Atinary Technologies

Atinary Technologies is the pioneer of Self-Driving Labs ®, a term its founders coined in 2017. Atinary's mission is to augment humans with AI and robotics to drive a Moore's Law of Discovery, exponentially accelerating the discovery of breakthrough molecules and materials to tackle planetary challenges in health, energy, food, and sustainability. Atinary owns a vertically integrated technology stack and offers its agentic AI platform SDLabs® and lab-validated datasets. SDLabs users can explore vastly larger chemical spaces and run complex experiments faster than ever, unlocking results that are out of reach using traditional R&D methods, as demonstrated in published work with world-renowned companies and universities. Atinary's ecosystem partners include ABB Robotics, Agilent, AWS, Bruker, Chemspeed, and Mettler-Toledo. Headquartered in Menlo Park, California, with operations in Boston and Lausanne. Learn more at www.atinary.com and contact us at contact@atinary.com.

Atinary Technologies

Atinary Self-Driving Lab integrating Chemspeed robotics, a Fourier 80 FT-NMR, and Atinary's SDLabs agentic AI platform into a closed-loop workflow. The system automates liquid and solid reagent addition, catalyst addition, reaction execution, sampling with filtration, and inline NMR analysis, across many chemical reactions, including Suzuki and Buchwald-Hartwig. Scientists control the platform via SDLabs, leveraging AI agents to design experiments, navigate molecular spaces, execute runs, visualize and interpret results, and act on AI-guided recommendations for the next experiments, compounding the information each cycle in an R&D flywheel. These integrated systems can solve challenges that are intractable with traditional methods.